Your browser doesn't support javascript.
loading
Clinical experience with integrase inhibitors in HIV-2-infected individuals in Spain.
Requena, S; Lozano, A B; Caballero, E; García, F; Nieto, M C; Téllez, R; Fernández, J M; Trigo, M; Rodríguez-Avial, I; Martín-Carbonero, L; Miralles, P; Soriano, V; de Mendoza, C.
Afiliación
  • Requena S; Puerta de Hierro University Hospital and Research Institute, Madrid, Spain.
  • Lozano AB; Hospital de Poniente, Almeria, Spain.
  • Caballero E; Hospital Vall d'Hebró, Barcelona, Spain.
  • García F; Hospital Universitario San Cecilio, Instituto de Investigación Ibs, Granada, Spain.
  • Nieto MC; Hospital de Basurto, Bilbao, Spain.
  • Téllez R; Fundación Jiménez-Díaz, Madrid, Spain.
  • Fernández JM; Hospital de Poniente, Almeria, Spain.
  • Trigo M; Complejo Hospitalario, Pontevedra, Spain.
  • Rodríguez-Avial I; Hospital Clínico San Carlos, Madrid, Spain.
  • Martín-Carbonero L; Hospital Universitario La Paz, Madrid, Spain.
  • Miralles P; Hospital Universitario Gregorio Marañón, Madrid, Spain.
  • Soriano V; Hospital Universitario La Paz, Madrid, Spain.
  • de Mendoza C; UNIR Health Sciences School, Madrid, Spain.
J Antimicrob Chemother ; 74(5): 1357-1362, 2019 05 01.
Article en En | MEDLINE | ID: mdl-30753573
BACKGROUND: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. METHODS: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. RESULTS: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). CONCLUSIONS: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-2 / Inhibidores de Integrasa VIH Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Antimicrob Chemother Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-2 / Inhibidores de Integrasa VIH Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: J Antimicrob Chemother Año: 2019 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido